Filing Details

Accession Number:
0001209191-14-062970
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-10-10 21:40:26
Reporting Period:
2014-10-08
Filing Date:
2014-10-10
Accepted Time:
2014-10-10 21:40:26
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
876343 Biotime Inc BTX Biological Products, (No Disgnostic Substances) (2836) 943127919
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1235445 David Schlachet 1301 Harbor Bay Parkway
Alameda CA 94502
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Shares, No Par Value Acquisiton 2014-10-08 32,050 $3.12 32,050 No 4 P Indirect see footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect see footnote
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Shares Option to Purchase Common Shares Acquisiton 2014-07-01 20,000 $0.00 20,000 $3.11
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
20,000 2019-06-30 No 4 A Direct
Reported Derivative Holdings
Sec. Name Sec. Type Price Date Expiration Date Amount Remaning Holdings Nature of Ownership
Common Shares Option to Purchase Common Shares $2.86 2019-04-10 20,000 20,000 Direct
Expiration Date Amount Remaning Holdings Nature of Ownership
2019-04-10 20,000 20,000 Direct
Footnotes
  1. Shares acquired pursuant to a Stock Purchase Agreement dated October 3, 2014.
  2. All shares are owned by Schlachet Management Ltd., a privately held company of which Mr. Schlachet is the sole shareholder, chief executive officer, and director.
  3. Will become exercisable in four equal quarterly installments after the date of grant on July 1, 2014 based upon continued service on the board of directors.
  4. 5,000 options became exercisable on June 30, 2014 and the remaining 15,000 will become exercisable in three equal quarterly installments based upon continued service on the board of directors.